耐甲氧西林金黃色葡萄球菌（MRSA）是常見(jiàn)病原菌之一，并且其多重耐藥菌株對(duì)人類(lèi)健康造成了較大威脅。靶向毒力因子的MRSA抗毒力抑制劑可以在解決細(xì)菌感染問(wèn)題的同時(shí)有效避免多重耐藥的產(chǎn)生與發(fā)展，具有較大應(yīng)用潛力。目前已知MRSA抗毒力抑制劑包括靶向ClpP蛋白酶的澤蘭黃酮、槲皮苷，靶向轉(zhuǎn)肽酶A的異牡荊苷，靶向轉(zhuǎn)肽酶B的根皮素，靶向α-溶血素的胡椒堿、厚樸總酚，靶向生物膜的黃綿馬酸BB及綠原酸代謝產(chǎn)物等。就上述MRSA抗毒力抑制劑的藥理作用進(jìn)行綜述，旨在為MRSA抗毒力抑制劑的進(jìn)一步研發(fā)提供參考。

Methicillin-resistant Staphylococcus aureus (MRSA) is one of the common pathogenic bacteria and the multiple drugresistant MRSA strains have threatened people's health. Anti-virulence inhibitors which inhibit MRSA virulence by targeting important virulence factors can effectively avoid the generation and development of multiple drug resistance while solving the problem of bacterial infection. Therefore, the study in anti-virulence inhibitors has great potential. At present, Anti-virulence inhibitors include nepetin and quercetin targeting ClpP, isovitexin targeting sortase A, phloretin targeting sortase B, piperine and total magnolol targeting α-hemolysin, flavaspidic acid BB and chlorogenic acid metabolities targeting biofilm, etc.In this paper, the recent research results of pharmacological actions and possible future research direction of the anti-virulence inhibitors above are summarized as follows, in order to provide reference for the further research and development of anti-virulence inhibitors.

R965

吉林大學(xué)2021年大學(xué)生創(chuàng)新創(chuàng)業(yè)訓(xùn)練計(jì)劃項(xiàng)目（S202110183547）